Three decades have now elapsed since the world first became aware of a sexually transmitted virus called Human Immunodeficiency Virus (HIV) that caused a devastating disease called Acquired Immune Deficiency Syndrome (AIDS). In those early days, treatment options were limited and the time between diagnosis and death was short. There was widespread fear associated with AIDS and HIV and the risk of acquiring the 'killer' virus from sexual contact or otherwise. Fortunately, understanding of the virus and how to treat it progressed rapidly and by 1985 the Centers for Disease Control and Prevention (CDC) in Atlanta, USA was able to produce authoritative guidance on the risk of acquiring HIV in healthcare settings. The use of gowns, masks and isolation rooms to care for HIV patients was replaced by precautions targeted at the epidemiology of the virus with blood and blood-stained body fluids considered the primary risk (Pratt, 2003) .
In the intervening years, treatments for HIV have advanced considerably. For those fortunate enough to live in developed countries, while HIV is still not curable, most can expect to have a near normal lifespan on treatment with antiretrovirals, provided their infection is diagnosed early. However, effective treatment is dependent on diagnosis being made before CD4 counts fall below 350 cells/mm 3 and the emergence of rapid, point-of-care tests for HIV and CD4 has improved access to testing and reduced the time between infection to detection to less than 1 month (Shete, 2013) .
However, while HIV may have slipped from the top of the public's agenda, it remains an important public health problem. In 2013 there were estimated to be over 100,000 people living with HIV in the UK; a prevalence of 2.8/1000 population (3.7 in men, 1.9 in women). However, one-quarter of these were unaware of their infection and likely to pass on HIV through unprotected sex. In 2013, STI clinics in the UK performed more than 1 million HIV tests and 6000 new cases of HIV were diagnosed; 42% of these cases were diagnosed late with high CD4 counts and a reduced prospect of effective treatment (Yin et al., 2014) .
In the UK, the HIV epidemic is concentrated in men who have sex with men (MSM) and heterosexual African-African men and women; these groups account for 40% and 36% of people living with HIV, respectively. MSM account for 54% of all new diagnoses of HIV in the UK and the prevalence of HIV among MSM is relatively high, with one in 17 HIV positive nationally but one in eight in London. Co-infection with another STI is an important factor in HIV transmission as it increases the risk of both acquisition and transmission of the virus. Fifteen percent of new diagnoses of HIV have another STI, but in MSM this rises to a quarter (Yin et al., 2014) .
Trends in diagnosis of new cases of HIV in the UK
New diagnoses of HIV climbed rapidly from about 3000 annually in the early to mid-1990s to a peak of almost 8000 in 2005. Since then the number of new diagnoses have declined, primarily because of a reduction in cases among heterosexuals from high prevalence countries. However, this overall decline disguises an underlying increase in new diagnoses of HIV among MSM, especially young men. Modelling of unlinked anonymous testing data suggests that most MSM with undiagnosed HIV will have acquired their HIV recently, within the last 3 years. New diagnoses of HIV among older heterosexuals is also increasing, with one in five new diagnoses now in people aged over 50 years compared to only one in 14 in 2004 (Yin et al., 2014) .
Trends in HIV in Europe and USA
In Europe, there has been only a minimal decline in new diagnoses of HIV from 6.7 to 6.4 per 100,000 population between 2005 and 2014, although this latter rate is considerably higher (7.9/100,000 population) when the World Health Organization (WHO) European area which encompasses the Russian federation is included (European Centre for Disease Prevention and Control [ECDC], 2015). The picture in Europe is similar to the UK, with an increasing number and proportion of new diagnoses of HIV attributed to MSM, rising from 20% of cases in 2005 to 29% in 2014 (Pharris et al., 2005) . New diagnoses have declined in heterosexuals and, as in the UK, this is largely due to a large reduction in cases in foreign-born people. Although people who inject drugs accounted for only 2.9% of cases in 2014, they are more likely to present late. At the national level, there is considerable variation in population groups at risk. Some countries with a previously low prevalence of HIV such as Bulgaria, Croatia, Cyprus, Czech republic, Lithuania, Hungary, Romania and Slovakia, have seen significant increases in new diagnoses in the last decade largely driven by epidemics among MSM and/or drug users, and lack of accessible testing and treatment programmes (ECDC, 2015; Pharris et al., 2005) .
In the USA, the annual number of HIV diagnoses declined by 19% between 2005 and 2014. This decrease has been largely driven by marked reductions among heterosexuals (35%) and people who inject drugs (63%). Although MSM now account for 67% of new diagnoses and have increased by 6% between 2005 and 2014, the rate of increase has stabilised since 2010 (CDC, 2016) . African Americans are disproportionately affected by HIV, accounting for 44% of cases while representing only 12% of the population. Southern states also have the greatest burden of HIV; those affected are less likely to be aware of their HIV status and the death rate in some Southern states is approaching 30%, which is three times higher than some other states (CDC 2016).
Progress in strategies to prevent HIV
In the UK, the availability and accessibility of free treatment has resulted in a high treatment coverage (estimated as 66% of all people living with HIV, diagnosed and undiagnosed). Patients tend to start their treatment early when the CD4 count in still above 350 cells/mm3, reducing the risk of transmission to other partners and adherence to treatment is high at 95% after 12 months (Yin et al., 2014) .
Worldwide, the picture is generally improving but still mixed. The United Nations General Assembly Special Session on HIV/AIDS in 2001 saw significant commitment made for a comprehensive response to HIV including universal access to HIV prevention, treatment, care and support for all in need. As a result, there have been a rapid expansion and improvements in HIV/AIDS programmes and a worldwide decline in new HIV infections of 35% between 2000 (WHO, 2016 . In 15 high burden countries, HIV prevalence has declined by more than 25% among young people aged 15-24 years. These programmes have extended access to antiretroviral therapy (ART) in low-and middle-income countries, with 35% of those estimated to be in need receiving therapy by 2009, and 53% of pregnant women with HIV having access to ART to prevent transmission of HIV to their babies. Significant reductions in the costs have seen the median cost of ART reduce to US$ 137 per person per year (WHO, 2011) . However, with a global prevalence of 33 million cases, new cases continue to outstrip those on treatment and the incidence of HIV increasing in some regions, including eastern Europe and central Asia. Sub-Saharan Africa accounts for 68% of cases of HIV, with women and young people disproportionately affected and transmission driven by gender inequality and harmful social norms. Prevention strategies need a stronger focus on the needs of women, girls and other vulnerable populations to improve their access to sexual and reproductive health services and education during formative adolescent years (WHO, 2011) .
Changing behaviour remains the cornerstone of strategies to prevent the transmission of the virus, in particular the use of condoms and reduction in number of sexual partners, and there is now evidence that male circumcision also reduces the risk of HIV acquisition (Rennie, 2007) . Other biological strategies are also under development. Work on developing an effective vaccine has yet to find an approach with more than 30% efficacy, but adherence to treatment with ART has been shown to reduce the risk of transmitting the virus to a sexual partner by 96% and is critical to preventing mother-to-child transmission (Shete, 2013) . The PROUD study is investigating the use of ART as pre-exposure prophylaxis (PrEP) to reduce HIV transmission to those at high risk of acquisition. Early indications are that is effective in preventing acquisition in MSM (Yin et al., 2014) .
In the UK, improved survival and more cases diagnosed at older age has meant that the proportion of people living with HIV has more than doubled since 2004 and now 27% of them are aged 50 years or older. Despite this more positive outlook for people living with HIV, HIV infection is still associated with significant stigma. In a recent national survey, of the 710 respondents, 63% were concerned about their HIV status being disclosed to others, 39% had experience unauthorised disclosure and 11% discrimination in the previous year (Yin et al., 2014) .
Disclosure of HIV status
Thousands of people newly diagnosed with HIV face the challenge of deciding who and how they will disclose their HIV status to their sexual partners. Supporting people living with HIV to make this very personal decision about disclosure is critical to reducing the risk of HIV transmission and yet is particularly complex in adolescents who have many other vulnerabilities in relation to their personal and sexual identify. Our hearts must surely go out to any teenager in this predicament as navigating their way through sexual activity is already fraught with enormous emotional, psychological and social challenges. In this issue of JIP we have two fascinating papers on the issue of disclosure of HIV status among young people. Carrie Grainger explores the motivations, challenges and barriers faced by young people in relation disclosure of their HIV status, and the Journal of Infection Prevention 18 (1) cultural and social norms that affect their decision-making. Leichenstien et al. offer some practical insights into counselling HIV-positive adolescents about sexual disclosure from a US perspective. Using two vignettes, they discuss a range of strategies that can be used to help adolescents develop scripts for handling disclosure and build their confidence in managing their sexual lives with HIV. In addition, the authors identify the adverse effect of legal requirements for HIV disclosure, which not only legitimises the stigma of the infection, but also increases the risk of secrecy. These two papers are an important reminder that while in the western world many now perceive HIV as a chronic condition rather than a life-threatening disease, the infection is still associated with significant stigma and fear. Adolescents are particularly vulnerable to acquiring sexual transmitted disease though risky sexual behaviour. Understanding how to support and facilitate young people living with HIV through the process of disclosing their status to their sexual partners is therefore critical to reducing the risk of HIV transmission.
